ofloxacin has been researched along with Bacterial Infections in 294 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Bacterial Infections: Infections by bacteria, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ratio of AUC from the PPK model vs MIC as the PD parameter can be applied in a dose-finding trial of antofloxacin in treatment of bacterial infections." | 9.16 | Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers. ( He, YC; Huang, JH; Li, YF; Wang, K; Yin, F; Zheng, QS, 2012) |
| "To evaluate the clinical efficacy and safety of antofloxacin hydrochloride tablet for the treatment of acute bacterial infections." | 9.15 | [A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections]. ( Chen, P; Cui, H; Huang, WX; Jia, ZP; Li, DT; Mao, GG; Wen, AD; Xiao, YH; Xiu, QY; Xue, F; Yang, GP, 2011) |
| "To evaluate the clinical efficiency and safety of intravenous levofloxacin in the treatment of bacterial infections at a dose of 500 mg once a day." | 9.14 | [The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial]. ( , 2009) |
| "The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe." | 9.13 | Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008) |
| "This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days." | 9.12 | Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006) |
| "Levofloxacin has excellent activity against common respiratory pathogens and therefore is likely to be effective in treating children with persistent or recurrent otitis media." | 9.12 | An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. ( Arguedas, A; Blumer, J; Dagan, R; Leibovitz, E; McNeeley, DF; Melkote, R; Noel, GJ; Pichichero, M, 2006) |
| "5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia." | 9.11 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 9.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 9.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia." | 9.11 | Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005) |
| "A multicentre randomized controlled clinical trial was conducted to compare sparfloxacin versus ofloxacin in the treatment of acute bacterial infections." | 9.10 | [Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections]. ( Cai, Y; Liang, D; Miao, J; Qiu, D; Wen, C; Xu, N, 2002) |
| "To compare the safety and efficacy of oral azithromycin and levofloxacin in the treatment of outpatients with acute bacterial exacerbations of chronic bronchitis (ABECB)." | 9.10 | Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. ( Amsden, GW; Baird, IM; Simon, S; Treadway, G, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 9.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "To evaluate the efficacy and safety of sparfloxacin in the treatment of bacterial infections." | 9.09 | [A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections]. ( Hu, D; Hu, P; Jiang, S; Jiang, Y; Li, S; Wang, Q; Zhu, L; Zou, Q, 1999) |
| "One hundred twenty-three cirrhotics with uncomplicated spontaneous bacterial peritonitis (no septic shock, grade II-IV hepatic encephalopathy, serum creatinine level of > 3 mg/dL, and gastrointestinal hemorrhage or ileus) were randomly given oral ofloxacin (64 patients) or intravenous cefotaxime (59 patients)." | 9.08 | Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. ( Arroyo, V; Bañares, R; Castells, L; Clemente, G; Follo, A; Forné, M; Guarner, C; Jimenez De Anta, MT; Llovet, JM; Marco, F; Navasa, M; Planas, R; Rimola, A; Rodés, J; Vargas, V, 1996) |
| "To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis." | 9.08 | Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. ( Anthony, KE; Fowler, CL; Kim, SS; Kopp, EJ; LoCoco, JM; Sydnor, TA, 1998) |
| "A multicentric study was conducted to evaluate the clinical efficacy and tolerance of ofloxacin in the treatment of chronic sinusitis and chronic otitis (CSOM) in outpatients." | 9.07 | Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients. ( Cohen, B; Gehanno, P, 1993) |
| "An exclusively oral regimen, in this case ofloxacin, may be substituted for parenteral therapy in selected patients with pneumonia." | 9.07 | Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. ( Alessi, P; Bittner, MJ; Iannini, P; Makris, AT; McCloskey, RV; Morris, JF; Sanders, WE; Trenholme, GM, 1991) |
| "128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial." | 9.07 | [Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991) |
| "Forty six patients who developed 48 episodes of peritonitis while on CAPD were randomised to receive either oral ofloxacin or intraperitoneal (i." | 9.07 | A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). ( Chan, CY; Cheng, IK; Wong, WT, 1991) |
| "Our study of 28 carefully selected patients proved that ofloxacin is a safe and effective drug for mild to moderately severe community-acquired pneumonia." | 9.07 | Treatment of community-acquired pneumonia with ofloxacin. ( Charoenratanakul, S; Nana, A; Permpikul, C; Thamlikitkul, V; Youngchaiyud, P, 1991) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 9.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "Forty-one hospitalized adult patients of bronchiectasis (non-cystic fibrotic) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days." | 9.06 | Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. ( Chan, JC; Chau, PY; Ip, M; Lam, WK; Leung, YK; Sham, MK; So, SY, 1989) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 9.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "A randomized, open, prospective study including 45 patients with either soft tissue infections (29 cases) or pneumonia (15 cases) after surgical intervention and one case having both indications was carried out with ofloxacin." | 9.06 | Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin. ( Fritzen, T; Marx, E; Uy, J, 1986) |
| "ofloxacin has established efficacy in the treatment of a wide variety of urinary tract infections, although, like other fluoroquinolones, it should be used rationally to preserve its activity." | 8.80 | Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. ( Balfour, JA; Lamb, HM; Onrust, SV, 1998) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 7.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "The pharmacodynamic targets representing 90% probability thresholds for bacterial eradication were determined in patients with complicated urinary tract infections (UTIs) treated with 500mg of levofloxacin every 24h for 7-14 days." | 7.76 | Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ( Arakawa, S; Deguchi, T; Matsumoto, T; Monden, K; Nakane, K; Shimizu, T; Yasuda, M, 2010) |
| "To describe the effect of a combination prophylactic regimen of levofloxacin, a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class, with either penicillin or doxycycline on the changing epidemiology of bacterial infections and antimicrobial resistance patterns of isolated organisms in the allogeneic hematopoietic stem cell transplant (HSCT) patient population." | 7.76 | Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. ( Barreto, JN; Estes, LL; Therriault, BL; Wilson, JW, 2010) |
| "To report six cases of corneal deposits after administration of topical ofloxacin in the treatment of bacterial keratitis." | 7.74 | Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. ( McElvanney, A; Mitra, A; Tsesmetzoglou, E, 2007) |
| "The pharmacokinetics of levofloxacin and outcome of levofloxacin therapy in critically ill patients with ventilator-associated pneumonia (VAP) were assessed." | 7.74 | Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ( Benko, R; Doro, P; Gardi, J; Hajdu, E; Matuz, M; Molnar, A; Nagy, E; Peto, Z; Soos, G, 2007) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 7.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections." | 7.72 | Tissue and serum levofloxacin concentrations in diabetic foot infection patients. ( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 7.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "In a prospective study, 70 men suffering from uncomplicated acute unilateral epididymitis were treated initially with 2 x 200 mg ofloxacin p." | 7.68 | [Initial therapy of acute unilateral epididymitis using ofloxacin. I. Clinical and microbiological findings]. ( Friedrich, HJ; Garbe, C; Harbrecht, J; Kleinschmidt, K; Schiefer, HG; Weidner, W; Weissbach, L, 1990) |
| "Ofloxacin (OFLX), a new pyridonecarboxylic acid derivative for oral use, was administered in the treatment of 22 cases of bacterial prostatitis (acute 4, chronic 18)." | 7.67 | [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. ( Ando, K; Moriguchi, R; Naide, Y; Suzuki, K; Tamai, H, 1984) |
| "From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7)." | 7.67 | Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. ( Bernard, E; Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R, 1989) |
| "After ascertaining the bacterial spectrum in 105 patients with Otitis media acutissima, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the efficacy of oral therapy with ofloxacin in five patients from each of these groups was assessed." | 7.67 | [Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences]. ( Lenarz, T, 1986) |
| "Ofloxacin diffusion into cerebrospinal fluid (CSF) was evaluated in nine patients with bacterial meningitis." | 7.67 | Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis. ( Bru, JP; Croize, J; Fourtillan, JB; Guyot, A; Leduc, D; Lefèbvre, MA; Micoud, M; Stahl, JP, 1986) |
| "Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)." | 6.74 | Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009) |
| "Bacterial infection is a common complication after allogeneic bone marrow transplantation." | 6.67 | Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin). ( Arlet, C; Bourdeau, H; Devergie, A; Gluckman, E; Hirsch, I; Perol, Y; Roudet, C, 1991) |
| "Levofloxacin (Levaquin) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens." | 6.42 | Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. ( Croom, KF; Goa, KL, 2003) |
| " A higher dosage of sequential levofloxacin 750mg once daily proved as effective as intravenous ticarcillin/clavulanic acid (+/- oral switch to amoxicillin/clavulanic acid) in the treatment of complicated skin and skin structure infections." | 6.41 | Levofloxacin: an updated review of its use in the treatment of bacterial infections. ( Figgitt, DP; Hurst, M; Lamb, HM; Scott, LJ, 2002) |
| "The ofloxacin MICs were inoculum dependent and ranged from 0." | 5.27 | Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. ( Fujita, K; Fukuda, Y; Koga, H; Nagasawa, M; Nakazato, H; Saito, A; Sawatari, K; Shigeno, Y; Suzuyama, Y; Tomonaga, A, 1985) |
| "The ratio of AUC from the PPK model vs MIC as the PD parameter can be applied in a dose-finding trial of antofloxacin in treatment of bacterial infections." | 5.16 | Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers. ( He, YC; Huang, JH; Li, YF; Wang, K; Yin, F; Zheng, QS, 2012) |
| "To evaluate the clinical efficacy and safety of antofloxacin hydrochloride tablet for the treatment of acute bacterial infections." | 5.15 | [A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections]. ( Chen, P; Cui, H; Huang, WX; Jia, ZP; Li, DT; Mao, GG; Wen, AD; Xiao, YH; Xiu, QY; Xue, F; Yang, GP, 2011) |
| "To evaluate the clinical efficiency and safety of intravenous levofloxacin in the treatment of bacterial infections at a dose of 500 mg once a day." | 5.14 | [The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial]. ( , 2009) |
| "The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe." | 5.13 | Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008) |
| "This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days." | 5.12 | Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006) |
| "Levofloxacin has excellent activity against common respiratory pathogens and therefore is likely to be effective in treating children with persistent or recurrent otitis media." | 5.12 | An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. ( Arguedas, A; Blumer, J; Dagan, R; Leibovitz, E; McNeeley, DF; Melkote, R; Noel, GJ; Pichichero, M, 2006) |
| "5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia." | 5.11 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004) |
| "These findings suggest that, despite increasing rates of antimicrobial resistance, levofloxacin prophylaxis during neutropenia may have a beneficial impact on morbidity and infection-related mortality." | 5.11 | Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. ( Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H, 2005) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 5.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 5.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "0-g dose of a novel azithromycin microsphere formulation with that of 10 days of levofloxacin, 500 mg/d, when used to treat adults with uncomplicated acute bacterial maxillary sinusitis (ABS)." | 5.11 | Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. ( Breen, JD; Emparanza, P; Lesinskas, E; Murray, JJ; Tawadrous, M, 2005) |
| "We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia." | 5.11 | Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005) |
| "Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization." | 5.11 | Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. ( Billingham, L; Bower, M; Cullen, M; Fernando, I; Gaunt, C; Gollins, S; Hastings, M; Huddart, R; Rea, D; Simmonds, P; Stanley, A; Steven, N; Stuart, N, 2005) |
| "A multicentre randomized controlled clinical trial was conducted to compare sparfloxacin versus ofloxacin in the treatment of acute bacterial infections." | 5.10 | [Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections]. ( Cai, Y; Liang, D; Miao, J; Qiu, D; Wen, C; Xu, N, 2002) |
| "To compare the safety and efficacy of oral azithromycin and levofloxacin in the treatment of outpatients with acute bacterial exacerbations of chronic bronchitis (ABECB)." | 5.10 | Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. ( Amsden, GW; Baird, IM; Simon, S; Treadway, G, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 5.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "Levofloxacin is a useful quinolone for patients infected with osteomyelitis or tuberculosis." | 5.09 | [Tolerability and safety of levofloxacinin long-term treatment]. ( Almela, M; Alvárez, JL; García, S; Mensa, J; Ortega, M; Soriano, A; Soriano, E; Tomás, X, 2000) |
| "To evaluate the efficacy and safety of sparfloxacin in the treatment of bacterial infections." | 5.09 | [A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections]. ( Hu, D; Hu, P; Jiang, S; Jiang, Y; Li, S; Wang, Q; Zhu, L; Zou, Q, 1999) |
| "One hundred twenty-three cirrhotics with uncomplicated spontaneous bacterial peritonitis (no septic shock, grade II-IV hepatic encephalopathy, serum creatinine level of > 3 mg/dL, and gastrointestinal hemorrhage or ileus) were randomly given oral ofloxacin (64 patients) or intravenous cefotaxime (59 patients)." | 5.08 | Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. ( Arroyo, V; Bañares, R; Castells, L; Clemente, G; Follo, A; Forné, M; Guarner, C; Jimenez De Anta, MT; Llovet, JM; Marco, F; Navasa, M; Planas, R; Rimola, A; Rodés, J; Vargas, V, 1996) |
| "To compare the cost-effectiveness of sequential intravenous-to-oral ofloxacin versus intravenous-to-oral standard switch therapy for the treatment of patients with sepsis who are hospitalized with bacterial infections." | 5.08 | Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. ( Paladino, JA; Partsch, DJ, 1997) |
| "To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis." | 5.08 | Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. ( Anthony, KE; Fowler, CL; Kim, SS; Kopp, EJ; LoCoco, JM; Sydnor, TA, 1998) |
| "A multicentric study was conducted to evaluate the clinical efficacy and tolerance of ofloxacin in the treatment of chronic sinusitis and chronic otitis (CSOM) in outpatients." | 5.07 | Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients. ( Cohen, B; Gehanno, P, 1993) |
| "Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections." | 5.07 | Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. ( Watanabe, A, 1991) |
| "In a multicentre non-randomized open prospective study, 124 patients hospitalized in medical infectious disease or intensive care units, with severe community and hospital-acquired bacterial infections were treated with 15 mg/kg body weight amikacin in a once-daily dose given as a 30 min iv infusion, combined with other antibiotics." | 5.07 | Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. ( Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O, 1991) |
| "An exclusively oral regimen, in this case ofloxacin, may be substituted for parenteral therapy in selected patients with pneumonia." | 5.07 | Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. ( Alessi, P; Bittner, MJ; Iannini, P; Makris, AT; McCloskey, RV; Morris, JF; Sanders, WE; Trenholme, GM, 1991) |
| "128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial." | 5.07 | [Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991) |
| "Forty six patients who developed 48 episodes of peritonitis while on CAPD were randomised to receive either oral ofloxacin or intraperitoneal (i." | 5.07 | A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). ( Chan, CY; Cheng, IK; Wong, WT, 1991) |
| "Our study of 28 carefully selected patients proved that ofloxacin is a safe and effective drug for mild to moderately severe community-acquired pneumonia." | 5.07 | Treatment of community-acquired pneumonia with ofloxacin. ( Charoenratanakul, S; Nana, A; Permpikul, C; Thamlikitkul, V; Youngchaiyud, P, 1991) |
| "The efficacy and safety of oral ofloxacin were compared with those of vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients undergoing chemotherapy for hematologic malignancy." | 5.06 | Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. ( Bruckner, DA; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ, 1990) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 5.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "Forty-one hospitalized adult patients of bronchiectasis (non-cystic fibrotic) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days." | 5.06 | Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. ( Chan, JC; Chau, PY; Ip, M; Lam, WK; Leung, YK; Sham, MK; So, SY, 1989) |
| "The drug Ofloxacin was tried clinically on 54 patients with different bacterial infections." | 5.06 | [Clinical trial of ofloxacin (Tarivid R)]. ( Angelova, I; Belovezhdov, N; Talakova, Ch, 1988) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 5.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "A randomized, open, prospective study including 45 patients with either soft tissue infections (29 cases) or pneumonia (15 cases) after surgical intervention and one case having both indications was carried out with ofloxacin." | 5.06 | Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin. ( Fritzen, T; Marx, E; Uy, J, 1986) |
| "Thirteen hospitalized patients with various infections, five with typhoid fever, two with gastroenteritis, four with respiratory tract infection and two with biliary tract infection, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | 5.06 | Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report. ( Altucci, P; Briante, V; Cristiano, P; Leonessa, V; Morelli, G; Paradisi, F, 1986) |
| "ofloxacin has established efficacy in the treatment of a wide variety of urinary tract infections, although, like other fluoroquinolones, it should be used rationally to preserve its activity." | 4.80 | Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. ( Balfour, JA; Lamb, HM; Onrust, SV, 1998) |
| " Monitoring for toxicity is incompletely reliable in identifying all potential serious side effects such as the "temafloxacin syndrome." | 4.79 | Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. ( Goldstein, EJ, 1996) |
| "Corneal cross-linking (CXL) with riboflavin is being used more frequently for the treatment of therapy-resistant microbial keratitis, since increasing drug resistance and specific pathogens, e." | 3.80 | [Corneal cross-linking in microbial keratitis to prevent à chaud keratoplasty: a retrospective case series]. ( Ammermann, C; Cursiefen, C; Hermann, M, 2014) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 3.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "Ofloxacin is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase." | 3.77 | Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. ( Faulds, D; Todd, PA, 1991) |
| "The pharmacodynamic targets representing 90% probability thresholds for bacterial eradication were determined in patients with complicated urinary tract infections (UTIs) treated with 500mg of levofloxacin every 24h for 7-14 days." | 3.76 | Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ( Arakawa, S; Deguchi, T; Matsumoto, T; Monden, K; Nakane, K; Shimizu, T; Yasuda, M, 2010) |
| "To describe the effect of a combination prophylactic regimen of levofloxacin, a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class, with either penicillin or doxycycline on the changing epidemiology of bacterial infections and antimicrobial resistance patterns of isolated organisms in the allogeneic hematopoietic stem cell transplant (HSCT) patient population." | 3.76 | Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. ( Barreto, JN; Estes, LL; Therriault, BL; Wilson, JW, 2010) |
| "Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults." | 3.76 | [Levofloxacin in children]. ( Cohen, R; Grimprel, E, 2010) |
| "Ofloxacin is a 4-quinolone antibiotic with rapid bactericidal activity against a wide variety of organisms." | 3.76 | Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. ( Drew, RH; Gallis, HA, 1988) |
| "To report six cases of corneal deposits after administration of topical ofloxacin in the treatment of bacterial keratitis." | 3.74 | Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. ( McElvanney, A; Mitra, A; Tsesmetzoglou, E, 2007) |
| "The pharmacokinetics of levofloxacin and outcome of levofloxacin therapy in critically ill patients with ventilator-associated pneumonia (VAP) were assessed." | 3.74 | Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ( Benko, R; Doro, P; Gardi, J; Hajdu, E; Matuz, M; Molnar, A; Nagy, E; Peto, Z; Soos, G, 2007) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 3.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections." | 3.72 | Tissue and serum levofloxacin concentrations in diabetic foot infection patients. ( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004) |
| "When seven elderly patients with fever due to bacterial infection failed to respond to ofloxacin 300 mg/day for 3 days, we prescribed Mao-bushi-saishin-to for 7 days." | 3.70 | Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin. ( Kamei, T; Tomioka, H; Toriumi, Y, 2000) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 3.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "In order to determine the efficacy and safety of the new quinolone ofloxacin in the treatment of chronic lower respiratory disease, 674 patients (353 with chronic bronchitis, 212 with community-acquired pneumonia and 109 with hospital-acquired pneumonia) were treated with ofloxacin 200 mg twice a day." | 3.68 | Ofloxacin in lower respiratory tract infections. ( Petermann, W, 1991) |
| "In a prospective study, 70 men suffering from uncomplicated acute unilateral epididymitis were treated initially with 2 x 200 mg ofloxacin p." | 3.68 | [Initial therapy of acute unilateral epididymitis using ofloxacin. I. Clinical and microbiological findings]. ( Friedrich, HJ; Garbe, C; Harbrecht, J; Kleinschmidt, K; Schiefer, HG; Weidner, W; Weissbach, L, 1990) |
| "We evaluated the efficacy and toxicity of piperacillin-ofloxacin as an empiric treatment of fever in patients with neutropenia." | 3.68 | [Empirical treatment of febrile episodes in granulocytopenic patients with a combination of piperacillin and ofloxacin. Preliminary study]. ( Brisseau, JM; Feve, B; Grolleau, JY; Raffi, F; Reynaud, AE; Tiab, M, 1990) |
| "Ofloxacin (OFLX), a new pyridonecarboxylic acid derivative for oral use, was administered in the treatment of 22 cases of bacterial prostatitis (acute 4, chronic 18)." | 3.67 | [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. ( Ando, K; Moriguchi, R; Naide, Y; Suzuki, K; Tamai, H, 1984) |
| "From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7)." | 3.67 | Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. ( Bernard, E; Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R, 1989) |
| "Thirty-four hospitalized patients with various infections: 19 with typhoid fever, 4 with gastroenteritis, 7 with lower respiratory tract infections, 2 with biliary tract infections, 1 with brucellosis and 1 with infection of necrotic ulceration of the feet, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | 3.67 | Clinical experience with ofloxacin (DL-8280) in the therapy of various infections. ( Altucci, P; Cristiano, P; Iovene, MR; Mandia, L; Morelli, G; Paradisi, F, 1989) |
| "After ascertaining the bacterial spectrum in 105 patients with Otitis media acutissima, Otitis media chronica mesotympanalis and Otitis media chronica epitympanalis, the efficacy of oral therapy with ofloxacin in five patients from each of these groups was assessed." | 3.67 | [Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences]. ( Lenarz, T, 1986) |
| "Ofloxacin diffusion into cerebrospinal fluid (CSF) was evaluated in nine patients with bacterial meningitis." | 3.67 | Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis. ( Bru, JP; Croize, J; Fourtillan, JB; Guyot, A; Leduc, D; Lefèbvre, MA; Micoud, M; Stahl, JP, 1986) |
| "We investigated the clinical efficiency and safety of ofloxacin, a new fluoroquinolone, for the treatment of various documented bacterial infections in 26 patients (10 females, 16 males) aged 17 to 84 years." | 3.67 | [Evaluation of the use of ofloxacin in the treatment of various infections]. ( Bertrand, JL; Lucht, F; Peyramond, D; Salord, F; Tigaud, S; Vedrinne, JM, 1986) |
| "Ofloxacin, a new fluoroquinolone, was given to fifty patients (29 females and 21 males) aged 25 to 86 years with urinary tract infection or prostatitis." | 3.67 | [Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections]. ( Acar, JF; Guibert, J, 1986) |
| "Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)." | 2.74 | Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009) |
| "Levofloxacin was well tolerated during and for 1 month after therapy as evidenced by similar incidence and character of adverse events compared with nonfluoroquinolone antibiotics." | 2.73 | Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. ( Arguedas, A; Bagchi, P; Balis, DA; Blumer, JL; Bradley, JS; Duffy, CM; Gerbino, PG; Kauffman, RE; Noel, GJ, 2007) |
| "FE rate was greatest for testicular cancer (27." | 2.73 | Rational selection of patients for antibacterial prophylaxis after chemotherapy. ( Billingham, LJ; Cullen, MH; Gaunt, CH; Steven, NM, 2007) |
| "Tosufloxacin was as effective as levofloxacin when administered twice daily for 2 days as prophylaxis for TBP, which suggests that this regimen is useful for reducing the clinical and febrile infection rate following TBP." | 2.73 | Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. ( Ishitoya, S; Kamoto, T; Ogawa, O; Okumura, K; Segawa, T; Yamamoto, S, 2008) |
| " This pharmacokinetic modeling could be used to determine optimal treatment dose in clinical trials in a shorter time frame with fewer patients." | 2.69 | Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. ( Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V, 1998) |
| "Ofloxacin was used in the treatment of 124 patients with bronchopulmonary diseases, the diseases of the biliary system and other infectious inflammatory diseases of the internal organs." | 2.68 | [Clinico-pharmacologic aspects of the use of ofloxacin]. ( Belitskaia, RA; Dubova, MN; Krasavina, MIu; Kukes, VG; Posrednikova, TA, 1996) |
| "The clinical course and death rate in acute necrotizing pancreatitis (ANP) are largely determined by septic complications as part of bacterial invasion of the necrotic tissues." | 2.68 | [Antibiotic use in necrotizing pancreatitis. Results of a controlled study]. ( Beger, HG; Isenmann, R; Meyer, H; Schwarz, M, 1997) |
| "In a word, both drugs are effective in treating bacterial infections of digestive system, urinary system and respiratory tract." | 2.67 | [Clinical efficacy of ciprofloxacin and ofloxacin]. ( Jiang, SC; Miao, JZ; Wang, XF, 1994) |
| "Group A showed a lower incidence of bacterial infections than group B (20% vs." | 2.67 | Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. ( Beaugrand, M; Blaise, M; Levacher, S; Pateron, D; Pourriat, JL; Trinchet, JC, 1994) |
| "Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients." | 2.67 | Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. ( Accorsi, P; Betti, S; D'Antonio, D; Dell'Isola, M; Favalli, C; Fioritoni, G; Iacone, A; Parruti, G; Piccolomini, R; Quaglietta, AM, 1994) |
| "Oral ofloxacin was associated with a relatively low incidence of documented bacterial infection and related mortality, although it did not obviate the need for frequent empiric antimicrobial therapy due to a high incidence of febrile episodes." | 2.67 | Single-drug oral antibacterial prophylaxis with ofloxacin in BMT recipients. ( Arnold, R; Hay, B; Hertenstein, B; Kern, WV; Schmeiser, T, 1993) |
| "Ofloxacin therapy was administered an average of 45 days per patient, and was well tolerated." | 2.67 | Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. ( Eron, LJ; Gentry, LO, 1992) |
| "Bacterial infection is a common complication after allogeneic bone marrow transplantation." | 2.67 | Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin). ( Arlet, C; Bourdeau, H; Devergie, A; Gluckman, E; Hirsch, I; Perol, Y; Roudet, C, 1991) |
| " Dosage adjustment was made for patients in renal failure." | 2.67 | Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. ( Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) |
| "Ofloxacin was superior to co-trimoxazole in preventing infection in this population of neutropenic patients." | 2.67 | Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. ( Chan, TK; Chau, PY; Lam, WK; Liang, RH; So, SY; Todd, D; Yung, RW, 1990) |
| "Ofloxacin was well tolerated in the elderly patients." | 2.66 | Efficacy and safety of ofloxacin in elderly patients. ( Blomer, R; Bruch, K, 1987) |
| "Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation." | 2.66 | [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. ( Blomer, R; Bruch, K; Zahlten, RN, 1986) |
| "Ofloxacin was used at a dosage of 300 mg to 800 mg daily for three to 20 days in 206 cases of various infectious diseases in the otorhinolaryngological field such as otitis media, external otitis, paranasal sinusitis, tonsillitis and pharyngolaryngitis." | 2.66 | Clinical efficacy of ofloxacin in the treatment of otorhinolaryngological infections. ( Baba, S, 1986) |
| "Hospital-acquired and community-acquired bacterial infections have already put a heavy burden on the global health system." | 2.61 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. ( Zhang, B, 2019) |
| "Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections." | 2.47 | [Treatment and prevention of infections in cancer patients with neutropenia]. ( Sinkó, J, 2011) |
| "Levofloxacin (Levaquin) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin." | 2.44 | Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. ( Anderson, VR; Perry, CM, 2008) |
| "Levofloxacin (Levaquin) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens." | 2.42 | Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. ( Croom, KF; Goa, KL, 2003) |
| " A higher dosage of sequential levofloxacin 750mg once daily proved as effective as intravenous ticarcillin/clavulanic acid (+/- oral switch to amoxicillin/clavulanic acid) in the treatment of complicated skin and skin structure infections." | 2.41 | Levofloxacin: an updated review of its use in the treatment of bacterial infections. ( Figgitt, DP; Hurst, M; Lamb, HM; Scott, LJ, 2002) |
| "Levofloxacin has demonstrated clinical efficacy in the treatment of community-acquired respiratory-tract infections, genitourinary infections, skin and skin-structure infections, acute bacterial sinusitis, and infections of the head and neck." | 2.40 | Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? ( Ernst, EJ; Ernst, ME; Klepser, ME, 1997) |
| "Levofloxacin is a valuable addition to the group of fluoroquinolone antibiotics." | 2.40 | Levofloxacin. ( Norrby, SR, 1999) |
| "Levofloxacin has a tolerability profile similar to that of other oral fluoroquinolones, with gastrointestinal and central nervous system effects reported most commonly." | 2.39 | Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. ( Bryson, HM; Davis, R, 1994) |
| "Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria." | 2.38 | Oral ofloxacin: a critical review of the new drug application. ( Sanders, WE, 1992) |
| "Ofloxacin is a new fluoroquinolone with a spectrum of activity similar to other fluoroquinolones with activity which includes Chlamydia trachomatis, Mycobacterium spp." | 2.38 | Ofloxacin clinical pharmacokinetics. ( Bailey, EM; Lamp, KC; Rybak, MJ, 1992) |
| "Ciprofloxacin has better activity against gram-negative bacilli, an advantage which may be negated by ofloxacin's longer half-life and higher serum levels." | 2.38 | Ofloxacin vs ciprofloxacin: a comparison. ( Nicolau, D; Nightingale, CH; Quintiliani, R, 1992) |
| " However, the pharmacokinetic profile of ofloxacin is superior to that of ciprofloxacin, with more rapid absorption and a peak serum concentration several times higher." | 2.37 | Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. ( Campoli-Richards, DM; Monk, JP, 1987) |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | 2.37 | Symposium on antimicrobial agents. The quinolones. ( Walker, RC; Wright, AJ, 1987) |
| " It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens." | 2.37 | Review of the 4-quinolones. ( Eggleston, M; Park, SY, 1987) |
| "Levofloxacin seems to be a good alternative treatment for patients with uncomplicated spontaneous ascites infections." | 1.36 | A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. ( Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T, 2010) |
| " The incidence of adverse reactions was 1." | 1.34 | Post-marketing surveillance of the safety of levofloxacin in Japan. ( Kawai, H; Komiya, M; Matsumoto, T; Nakayasu, T; Shimada, J; Yamaguchi, H; Yokoyama, H, 2007) |
| " By the antibacterial activity and bioavailability sodium furasidin is advantages among the nitrofurans." | 1.33 | [Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. ( Ivanov, DV; Sidorenko, SV, 2005) |
| "Levofloxacin is a new, recently commercialized fluoroquinolone." | 1.32 | [Use of levofloxacin in the hospital]. ( Arnau, JM; Campany, D; Castells, X; Rigau, D; Vallano, A, 2003) |
| "Levofloxacin was predominantly prescribed for treating community-acquired infections (67." | 1.32 | [Observational study investigating the use of levofloxacin in ICU patients]. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sánchez, M, 2004) |
| "The optimal period of antibiotic treatment of hepatic failure with SBP should be from 7 days to 10 days." | 1.32 | [A prospective study on short period antibiotic treatment of hepatic failure complicated with spontaneous bacterial peritonitis]. ( Du, N; He, WP; Ji, W; Li, HW; Wang, HF; Xia, J; Zhao, P, 2004) |
| "Moxifloxacin was more potent than ofloxacin and ciprofloxacin against Gram-positive rods and anaerobic cocci." | 1.31 | Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. ( Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E, 2002) |
| "Levofloxacin was generally one to two dilutions more active than ofloxacin, while ciprofloxacin was active against aerobes (MIC < or = 1 mg/L) but less active against anaerobic strains (MIC90 < or = 16 mg/L)." | 1.30 | Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. ( Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV, 1998) |
| "Ofloxacin levels were determined in aqueous humor, vitreous humor, and serum by a bioassay." | 1.29 | Effect of inflammation on intraocular penetration of intravenous ofloxacin in albino rabbits. ( Gatti, G; Panozzo, G, 1995) |
| "Sparfloxacin was fourfold more active against Staphylococcus aureus and Streptococcus pneumoniae." | 1.29 | In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. ( Ahlén, S; Malmborg, AS, 1993) |
| "Ciprofloxacin was the quinolone of choice in 24/32 (75%) of assessable cases." | 1.29 | An audit of ciprofloxacin use in a district general hospital. ( Fenelon, LE; MacGowan, AP; Reeves, DS; Smyth, EG; Speirs, GE; Speller, DC; Wilcox, MH, 1995) |
| "The properties of ofloxacin such as a new mechanism of action, broad spectrum and high antimicrobial activity, 100-percent bioavailability and rapid penetration to the body tissues, etc." | 1.29 | [Use of ofloxacin in infections which do not readily respond to treatment]. ( Zalaudek, G, 1996) |
| "Levofloxacin was twofold [corrected] more active than ciprofloxacin against Streptococcus pneumoniae and 2- to 4-fold more active than ciprofloxacin against Staphylococcus aureus, Xanthomonas maltophilia, and Bacteroides fragilis." | 1.28 | In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. ( Barrett, JF; Foleno, B; Fu, KP; Isaacson, DM; Lafredo, SC; Rosenthale, ME; Tobia, AJ, 1992) |
| "Levofloxacin (LVFX, DR-3355) a new synthetic antibacterial agent, was evaluated pharmacokinetic and clinically in the field of obstetrics and gynecology and the following results were obtained." | 1.28 | [Pharmacokinetic and clinical evaluation of levofloxacin in obstetrical and gynecological field]. ( Hirayama, H; Matsuda, S; Oh, K, 1992) |
| "BMY 40062 and ofloxacin were more active than ciprofloxacin against Bacteroides fragilis and Clostridium difficile." | 1.28 | In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. ( Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989) |
| "Ofloxacin was more active against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Acinetobacter spp." | 1.27 | Antibacterial activity of ofloxacin and its mode of action. ( Aoyama, H; Fujii, T; Inoue, Y; Mitsuhashi, S; Sato, K, 1986) |
| "13 micrograms/ml for a dosage of 8." | 1.27 | [Our experience with ofloxacin in the treatment of osteoarticular infections]. ( Hermet, R; Levai, JP; Lopitaux, R; Sirot, J; Terver, S, 1988) |
| " The study indicates that ofloxacin is a safe and effective agent in the treatment of various infections." | 1.27 | Clinical safety and efficacy of ofloxacin. ( Concia, E; Grossi, P; Malfitano, A; Marone, P; Perversi, L, 1988) |
| "Treatment with ofloxacin in 15 patients with chronic renal failure at different stages is reported with respect to patients undergoing hemodialysis treatment." | 1.27 | [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results]. ( Dörfler, A; Schulz, W, 1986) |
| " The authors thus recommend a dosage of 400 mg of ofloxacin three to five hours prior to surgery for middle ear infection." | 1.27 | Tissue concentrations of ofloxacin in the middle ear. ( Thorn, V, 1987) |
| "Ofloxacin was active against all but one (Pseudomonas aeruginosa) blood culture isolates." | 1.27 | Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986) |
| "The ofloxacin MICs were inoculum dependent and ranged from 0." | 1.27 | Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. ( Fujita, K; Fukuda, Y; Koga, H; Nagasawa, M; Nakazato, H; Saito, A; Sawatari, K; Shigeno, Y; Suzuyama, Y; Tomonaga, A, 1985) |
| "Ofloxacin is a new quinolone carboxylic acid compound." | 1.27 | In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. ( Kumada, T; Neu, HC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 81 (27.55) | 18.7374 |
| 1990's | 107 (36.39) | 18.2507 |
| 2000's | 84 (28.57) | 29.6817 |
| 2010's | 21 (7.14) | 24.3611 |
| 2020's | 1 (0.34) | 2.80 |
| Authors | Studies |
|---|---|
| Jinbo, Y | 1 |
| Kondo, H | 1 |
| Inoue, Y | 2 |
| Taguchi, M | 1 |
| Tsujishita, H | 1 |
| Kotera, Y | 2 |
| Sakamoto, F | 1 |
| Tsukamoto, G | 1 |
| Cormier, R | 1 |
| Burda, WN | 1 |
| Harrington, L | 1 |
| Edlinger, J | 1 |
| Kodigepalli, KM | 1 |
| Thomas, J | 1 |
| Kapolka, R | 1 |
| Roma, G | 1 |
| Anderson, BE | 1 |
| Turos, E | 1 |
| Shaw, LN | 1 |
| Boibessot, T | 1 |
| Zschiedrich, CP | 1 |
| Lebeau, A | 1 |
| Bénimèlis, D | 1 |
| Dunyach-Rémy, C | 1 |
| Lavigne, JP | 1 |
| Szurmant, H | 1 |
| Benfodda, Z | 1 |
| Meffre, P | 1 |
| Shrestha, SK | 1 |
| Kril, LM | 1 |
| Green, KD | 1 |
| Kwiatkowski, S | 1 |
| Sviripa, VM | 1 |
| Nickell, JR | 1 |
| Dwoskin, LP | 1 |
| Watt, DS | 1 |
| Garneau-Tsodikova, S | 1 |
| Zhang, B | 1 |
| Galhano, J | 1 |
| Marcelo, GA | 1 |
| Duarte, MP | 1 |
| Oliveira, E | 1 |
| Ammermann, C | 1 |
| Cursiefen, C | 1 |
| Hermann, M | 1 |
| Naber, KG | 3 |
| Roscher, K | 3 |
| Botto, H | 1 |
| Schaefer, V | 1 |
| Lipsky, BA | 1 |
| Holroyd, KJ | 1 |
| Zasloff, M | 1 |
| Yakar, T | 1 |
| Güçlü, M | 1 |
| Serin, E | 1 |
| Alişkan, H | 1 |
| Husamettin, E | 1 |
| Iakovlev, VP | 1 |
| Núñez Otero, V | 1 |
| Limeres Posse, J | 1 |
| Carmona, IT | 1 |
| Diz Dios, P | 1 |
| Shigemura, K | 1 |
| Yasufuku, T | 1 |
| Yamashita, M | 1 |
| Arakawa, S | 2 |
| Fujisawa, M | 1 |
| Deguchi, T | 1 |
| Nakane, K | 1 |
| Yasuda, M | 1 |
| Shimizu, T | 1 |
| Monden, K | 1 |
| Matsumoto, T | 2 |
| Petrosillo, N | 1 |
| Mirone, V | 1 |
| Therriault, BL | 1 |
| Wilson, JW | 1 |
| Barreto, JN | 1 |
| Estes, LL | 1 |
| Hibbard, ML | 1 |
| Kopelman, TR | 1 |
| O'Neill, PJ | 1 |
| Maly, TJ | 1 |
| Matthews, MR | 1 |
| Cox, JC | 1 |
| Vail, SJ | 1 |
| Quan, AN | 1 |
| Drachman, DA | 1 |
| Grimprel, E | 1 |
| Cohen, R | 1 |
| Rahman, MM | 1 |
| Khan, MA | 1 |
| Turel, I | 1 |
| Kljun, J | 1 |
| Perdih, F | 1 |
| Morozova, E | 1 |
| Bakulev, V | 1 |
| Kasyanenko, N | 1 |
| Byl, JA | 1 |
| Osheroff, N | 1 |
| Wagenlehner, F | 1 |
| Xiao, YH | 1 |
| Cui, H | 1 |
| Xue, F | 1 |
| Huang, WX | 1 |
| Xiu, QY | 1 |
| Li, DT | 1 |
| Chen, P | 1 |
| Jia, ZP | 1 |
| Wen, AD | 1 |
| Yang, GP | 1 |
| Mao, GG | 1 |
| Sinkó, J | 1 |
| Mohan, P | 1 |
| Venkataraman, J | 1 |
| Azéma, J | 1 |
| Guidetti, B | 1 |
| Korolyov, A | 1 |
| Kiss, R | 1 |
| Roques, C | 1 |
| Constant, P | 1 |
| Daffé, M | 1 |
| Malet-Martino, M | 1 |
| Schuette, W | 1 |
| Nagel, S | 1 |
| von Weikersthal, LF | 1 |
| Pabst, S | 1 |
| Schumann, C | 1 |
| Deuss, B | 1 |
| Salm, T | 1 |
| Dickgreber, N | 1 |
| Saribas, Z | 1 |
| Ergun, H | 1 |
| Mamuk, S | 1 |
| Köseoglu-Eser, O | 1 |
| Melli, M | 1 |
| Li, YF | 1 |
| Wang, K | 1 |
| Yin, F | 1 |
| He, YC | 1 |
| Huang, JH | 1 |
| Zheng, QS | 1 |
| Butler, NJ | 1 |
| Suhler, EB | 1 |
| Hurst, M | 1 |
| Lamb, HM | 2 |
| Scott, LJ | 1 |
| Figgitt, DP | 1 |
| Weiss, LR | 1 |
| Behra-Miellet, J | 1 |
| Dubreuil, L | 2 |
| Jumas-Bilak, E | 1 |
| Cai, Y | 1 |
| Liang, D | 1 |
| Xu, N | 1 |
| Miao, J | 1 |
| Qiu, D | 1 |
| Wen, C | 1 |
| Matsuzaki, K | 2 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 2 |
| Hasegawa, M | 2 |
| Kobayashi, I | 2 |
| Amsden, GW | 1 |
| Baird, IM | 1 |
| Simon, S | 1 |
| Treadway, G | 1 |
| Jeon, SS | 1 |
| Woo, SH | 1 |
| Hyun, JH | 1 |
| Choi, HY | 1 |
| Chai, SE | 1 |
| Bundrick, W | 1 |
| Heron, SP | 1 |
| Ray, P | 1 |
| Schiff, WM | 1 |
| Tennenberg, AM | 2 |
| Wiesinger, BA | 1 |
| Wright, PA | 1 |
| Wu, SC | 2 |
| Zadeikis, N | 1 |
| Kahn, JB | 4 |
| Castells, X | 1 |
| Vallano, A | 1 |
| Campany, D | 1 |
| Rigau, D | 1 |
| Arnau, JM | 1 |
| Croom, KF | 1 |
| Goa, KL | 1 |
| Cornely, OA | 1 |
| Wicke, T | 1 |
| Seifert, H | 1 |
| Bethe, U | 1 |
| Schwonzen, M | 1 |
| Reichert, D | 1 |
| Ullmann, AJ | 1 |
| Karthaus, M | 1 |
| Breuer, K | 1 |
| Salzberger, B | 1 |
| Diehl, V | 1 |
| Fätkenheuer, G | 1 |
| Alvarez-Lerma, F | 1 |
| Palomar, M | 1 |
| Olaechea, P | 1 |
| León, C | 1 |
| Sánchez, M | 1 |
| Bermejo, B | 1 |
| Felmingham, D | 1 |
| Lobmann, R | 1 |
| Ambrosch, A | 1 |
| Seewald, M | 1 |
| Dietlein, M | 1 |
| Zink, K | 1 |
| Kullmann, KH | 1 |
| Lehnert, H | 1 |
| Li, HW | 1 |
| Zhao, P | 1 |
| Wang, HF | 1 |
| Ji, W | 1 |
| He, WP | 1 |
| Du, N | 1 |
| Xia, J | 1 |
| Oberdorfer, K | 1 |
| Swoboda, S | 1 |
| Hamann, A | 1 |
| Baertsch, U | 1 |
| Kusterer, K | 1 |
| Born, B | 1 |
| Hoppe-Tichy, T | 1 |
| Geiss, HK | 1 |
| von Baum, H | 2 |
| Miravitlles, M | 1 |
| Torres, A | 1 |
| Lode, H | 1 |
| Eller, J | 1 |
| Linnhoff, A | 1 |
| Ioanas, M | 1 |
| Sinopal'nikov, AI | 1 |
| Romanovskiĭ, AG | 1 |
| Weber, P | 1 |
| Dib, C | 1 |
| Durand, C | 1 |
| Moniot-Ville, N | 1 |
| Reuter, S | 1 |
| Kern, WV | 2 |
| Sigge, A | 1 |
| Döhner, H | 1 |
| Marre, R | 1 |
| Kern, P | 1 |
| Anon, JB | 2 |
| Schaeffer, AJ | 1 |
| Gehanno, P | 2 |
| Pessey, JJ | 1 |
| Serrano, E | 1 |
| Murray, JJ | 1 |
| Emparanza, P | 1 |
| Lesinskas, E | 1 |
| Tawadrous, M | 1 |
| Breen, JD | 1 |
| Marple, BF | 1 |
| Bucaneve, G | 1 |
| Micozzi, A | 1 |
| Menichetti, F | 1 |
| Martino, P | 2 |
| Dionisi, MS | 1 |
| Martinelli, G | 1 |
| Allione, B | 1 |
| D'Antonio, D | 2 |
| Buelli, M | 1 |
| Nosari, AM | 1 |
| Cilloni, D | 1 |
| Zuffa, E | 1 |
| Cantaffa, R | 1 |
| Specchia, G | 1 |
| Amadori, S | 1 |
| Fabbiano, F | 1 |
| Deliliers, GL | 1 |
| Lauria, F | 1 |
| Foà, R | 1 |
| Del Favero, A | 1 |
| Cullen, M | 2 |
| Steven, N | 2 |
| Billingham, L | 2 |
| Gaunt, C | 1 |
| Hastings, M | 1 |
| Simmonds, P | 1 |
| Stuart, N | 1 |
| Rea, D | 1 |
| Bower, M | 1 |
| Fernando, I | 1 |
| Huddart, R | 1 |
| Gollins, S | 1 |
| Stanley, A | 1 |
| Baden, LR | 2 |
| Sidorenko, SV | 1 |
| Ivanov, DV | 2 |
| Nani, E | 1 |
| Anzivino, D | 1 |
| Lavitola, A | 1 |
| Lembo, M | 1 |
| Covelli, B | 1 |
| Giamarellou, H | 3 |
| Kanellakopoulou, K | 2 |
| Potel, G | 1 |
| Touze, MD | 1 |
| Reynaud, A | 1 |
| Courtieu, AL | 1 |
| Baron, D | 1 |
| Lo Bue, AM | 1 |
| Chisari, G | 1 |
| Fiorenza, G | 1 |
| Ferlito, S | 1 |
| Gismondo, MR | 1 |
| Marone, P | 2 |
| Concia, E | 2 |
| Quarta, V | 1 |
| Minoli, L | 1 |
| Carnevale, G | 1 |
| Pust, RA | 1 |
| Ackenheil-Koppe, HR | 1 |
| Gilbert, P | 1 |
| Weidner, W | 2 |
| Freifeld, AG | 1 |
| Sepkowitz, KA | 1 |
| Eller, P | 1 |
| Pechlaner, C | 1 |
| Ito, JI | 1 |
| Tegtmeier, BR | 1 |
| O'Donnell, MR | 1 |
| Pasqualotto, AC | 1 |
| Rosa, DD | 1 |
| Machado, AL | 1 |
| Almyroudis, NG | 1 |
| Segal, BH | 1 |
| Castagna, L | 1 |
| Santoro, A | 1 |
| Hadley, JA | 1 |
| Mitra, A | 1 |
| Tsesmetzoglou, E | 1 |
| McElvanney, A | 1 |
| Olapade-Olaopa, EO | 1 |
| Adebayo, SA | 1 |
| Sidirenko, SV | 1 |
| Soriano, A | 2 |
| García, S | 2 |
| Bori, G | 1 |
| Almela, M | 2 |
| Gallart, X | 1 |
| Macule, F | 1 |
| Sierra, J | 1 |
| Martínez, JA | 1 |
| Suso, S | 1 |
| Mensa, J | 2 |
| Grossman, RF | 1 |
| Ambrusz, ME | 1 |
| Fisher, AC | 1 |
| Khashab, MM | 1 |
| Arguedas, A | 2 |
| Dagan, R | 1 |
| Pichichero, M | 1 |
| Leibovitz, E | 1 |
| Blumer, J | 1 |
| McNeeley, DF | 1 |
| Melkote, R | 1 |
| Noel, GJ | 2 |
| Yamaguchi, H | 1 |
| Kawai, H | 1 |
| Yokoyama, H | 1 |
| Nakayasu, T | 1 |
| Komiya, M | 1 |
| Shimada, J | 1 |
| Khashab, M | 1 |
| Ambruzs, M | 1 |
| Catero, M | 1 |
| Khan, AA | 1 |
| Khan, A | 1 |
| Budanov, SV | 1 |
| Benko, R | 1 |
| Matuz, M | 1 |
| Doro, P | 1 |
| Peto, Z | 1 |
| Molnar, A | 1 |
| Hajdu, E | 1 |
| Nagy, E | 1 |
| Gardi, J | 1 |
| Soos, G | 1 |
| Bradley, JS | 1 |
| Kauffman, RE | 1 |
| Duffy, CM | 1 |
| Gerbino, PG | 1 |
| Bagchi, P | 1 |
| Balis, DA | 1 |
| Blumer, JL | 1 |
| Bindal, M | 1 |
| Krabak, B | 1 |
| Cullen, MH | 1 |
| Billingham, LJ | 1 |
| Gaunt, CH | 1 |
| Steven, NM | 1 |
| Ambrose, PG | 1 |
| Bhavnani, SM | 1 |
| Okusanya, OO | 1 |
| Jones, RN | 4 |
| Paglia, MR | 1 |
| Kahn, J | 1 |
| Drusano, GL | 2 |
| Anderson, VR | 1 |
| Perry, CM | 1 |
| Gwaltney, JM | 1 |
| Yamamoto, S | 1 |
| Ishitoya, S | 1 |
| Segawa, T | 1 |
| Kamoto, T | 1 |
| Okumura, K | 1 |
| Ogawa, O | 1 |
| Bauernfeind, A | 1 |
| Ullmann, U | 1 |
| Fujita, K | 2 |
| Nakano, M | 1 |
| Nonami, E | 1 |
| Shishiba, T | 1 |
| Katsumata, M | 1 |
| Horie, N | 1 |
| Watanabe, R | 1 |
| Kukita, A | 1 |
| Watanabe, S | 1 |
| Someya, T | 1 |
| Fujimori, I | 1 |
| Kobayashi, Y | 1 |
| Obana, M | 1 |
| Saito, A | 4 |
| Tomizawa, M | 1 |
| Nakayama, I | 1 |
| Hiraga, Y | 1 |
| Kikuchi, K | 1 |
| Yamamoto, A | 1 |
| Takebe, K | 1 |
| Saito, M | 1 |
| Seo, T | 1 |
| Matsubara, Y | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Ito, K | 2 |
| Konishi, K | 1 |
| Matsunaga, M | 1 |
| Yanagishita, T | 1 |
| Kosugi, M | 1 |
| Suzuki, K | 1 |
| Tamai, H | 1 |
| Naide, Y | 1 |
| Ando, K | 1 |
| Moriguchi, R | 1 |
| Sato, K | 3 |
| Matsuura, Y | 1 |
| Inoue, M | 2 |
| Une, T | 2 |
| Osada, Y | 1 |
| Ogawa, H | 1 |
| Mitsuhashi, S | 4 |
| Davis, R | 1 |
| Bryson, HM | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Yuen, AP | 1 |
| Chau, PY | 3 |
| Wei, WI | 1 |
| Maiche, AG | 1 |
| Muhonen, T | 1 |
| Gatti, G | 1 |
| Panozzo, G | 1 |
| Battista, C | 1 |
| Kane, MP | 1 |
| Moon, DG | 1 |
| Bailie, GR | 1 |
| Körner, RJ | 1 |
| McMullin, CM | 1 |
| Bowker, KA | 1 |
| White, LO | 1 |
| Reeves, DS | 2 |
| MacGowan, AP | 2 |
| Jiang, SC | 1 |
| Wang, XF | 1 |
| Miao, JZ | 1 |
| Blaise, M | 1 |
| Pateron, D | 1 |
| Trinchet, JC | 1 |
| Levacher, S | 1 |
| Beaugrand, M | 1 |
| Pourriat, JL | 1 |
| Hoban, DJ | 1 |
| Dholakia, N | 1 |
| Rolston, KV | 1 |
| Ho, DH | 1 |
| LeBlanc, B | 1 |
| Bodey, GP | 1 |
| Piccolomini, R | 1 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Parruti, G | 1 |
| Betti, S | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Dell'Isola, M | 1 |
| Favalli, C | 1 |
| Verhoest, P | 1 |
| Fernandez, H | 1 |
| Henry-Suchet, J | 1 |
| Orfila, J | 2 |
| Boulanger, JC | 1 |
| Sajben, P | 1 |
| Minárik, T | 1 |
| Tomásik, E | 1 |
| Mardiak, J | 1 |
| Danisovicovà, A | 1 |
| Trupl, T | 1 |
| Krcméry, V | 2 |
| Schmeiser, T | 1 |
| Hay, B | 1 |
| Hertenstein, B | 1 |
| Arnold, R | 1 |
| Malmborg, AS | 1 |
| Ahlén, S | 1 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 2 |
| Takahata, M | 2 |
| Todo, Y | 2 |
| Narita, H | 2 |
| Cohen, B | 1 |
| Heppt, W | 1 |
| Lutz, H | 1 |
| Speirs, GE | 1 |
| Fenelon, LE | 1 |
| Speller, DC | 1 |
| Smyth, EG | 1 |
| Wilcox, MH | 1 |
| Landau, Z | 1 |
| Arcavi, L | 1 |
| Resnitzky, P | 1 |
| Li, JT | 1 |
| Yoshida, M | 1 |
| Nakatsuka, K | 1 |
| Fujimoto, K | 1 |
| Yamamura, K | 1 |
| Hayashi, T | 1 |
| Osada, T | 1 |
| Sakurai, T | 1 |
| Navasa, M | 1 |
| Follo, A | 1 |
| Llovet, JM | 1 |
| Clemente, G | 1 |
| Vargas, V | 1 |
| Rimola, A | 1 |
| Marco, F | 1 |
| Guarner, C | 1 |
| Forné, M | 1 |
| Planas, R | 1 |
| Bañares, R | 1 |
| Castells, L | 1 |
| Jimenez De Anta, MT | 1 |
| Arroyo, V | 1 |
| Rodés, J | 1 |
| García-Tsao, G | 1 |
| Bertini, M | 1 |
| Freilone, R | 1 |
| Vitolo, U | 1 |
| Botto, B | 1 |
| Ciotti, R | 1 |
| Cinieri, S | 1 |
| Di Nota, A | 1 |
| Di Vito, F | 1 |
| Levis, A | 1 |
| Orsucci, L | 1 |
| Pini, M | 1 |
| Rota-Scalabrini, D | 1 |
| Todeschini, G | 1 |
| Resegotti, L | 1 |
| Goldstein, EJ | 3 |
| Waikakul, S | 1 |
| Penkitti, P | 1 |
| Nati, S | 1 |
| Choreoncholwanich, K | 1 |
| Zalaudek, G | 1 |
| Kukes, VG | 1 |
| Belitskaia, RA | 1 |
| Dubova, MN | 1 |
| Krasavina, MIu | 1 |
| Posrednikova, TA | 1 |
| Schwarz, M | 1 |
| Isenmann, R | 1 |
| Meyer, H | 1 |
| Beger, HG | 1 |
| Choi, KH | 2 |
| Hong, JS | 1 |
| Kim, SK | 1 |
| Lee, DK | 1 |
| Yoon, SJ | 1 |
| Choi, EC | 3 |
| Kim, JH | 2 |
| Kang, JA | 1 |
| Kim, YG | 1 |
| Kim, JW | 2 |
| Lee, JH | 2 |
| Kim, BK | 2 |
| Winkeltau, GJ | 1 |
| Töns, C | 1 |
| Bertram, P | 1 |
| Schumpelick, V | 1 |
| Partsch, DJ | 1 |
| Paladino, JA | 1 |
| Ernst, ME | 1 |
| Ernst, EJ | 1 |
| Klepser, ME | 1 |
| Preston, SL | 1 |
| Berman, AL | 1 |
| Fowler, CL | 2 |
| Chow, AT | 1 |
| Dornseif, B | 1 |
| Reichl, V | 1 |
| Natarajan, J | 1 |
| Corrado, M | 1 |
| Kuck, EM | 1 |
| Bouter, KP | 1 |
| Hoekstra, JB | 1 |
| Conemans, JM | 1 |
| Diepersloot, RJ | 1 |
| Hennenfent, BR | 1 |
| Feliciano, AE | 1 |
| Vychytil, A | 1 |
| Lorenz, M | 1 |
| Schneider, B | 1 |
| Hörl, WH | 1 |
| Haag-Weber, M | 1 |
| Nishimura, T | 1 |
| Abe, H | 1 |
| Ito, H | 1 |
| Ikeda, K | 1 |
| Oka, F | 1 |
| Yamamoto, M | 1 |
| Sydnor, TA | 1 |
| Kopp, EJ | 1 |
| Anthony, KE | 1 |
| LoCoco, JM | 1 |
| Kim, SS | 1 |
| Citron, DM | 2 |
| Hudspeth, M | 1 |
| Hunt Gerardo, S | 1 |
| Merriam, CV | 1 |
| Onrust, SV | 1 |
| Balfour, JA | 1 |
| Krupova, Y | 1 |
| Novotny, J | 1 |
| Sabo, A | 1 |
| Mateicka, F | 1 |
| Goldblatt, EL | 1 |
| Dohar, J | 1 |
| Nozza, RJ | 1 |
| Nielsen, RW | 1 |
| Goldberg, T | 1 |
| Sidman, JD | 1 |
| Seidlin, M | 1 |
| Mitsuyama, J | 1 |
| Yonezawa, M | 1 |
| Araki, H | 2 |
| Minami, S | 1 |
| Watanabe, Y | 1 |
| Redondo Sánchez, J | 1 |
| Koga, H | 2 |
| Aoyagi, K | 1 |
| Yoshimura, R | 1 |
| Kimura, Y | 1 |
| Iida, M | 1 |
| Fujishima, M | 1 |
| Hooper, DC | 3 |
| Kadiri, S | 1 |
| Ajayi, SO | 1 |
| Toki, RA | 1 |
| Koyama, H | 1 |
| Chiba, A | 1 |
| Omika, K | 1 |
| Harada, S | 1 |
| Kaneko, A | 1 |
| Sasaki, J | 1 |
| Raz, R | 1 |
| Raizenberg, C | 1 |
| Rohana, Y | 1 |
| Unamba-Oparah, I | 1 |
| Korfman, G | 1 |
| Yaniv, I | 1 |
| Asvanich, K | 1 |
| Fugpholngam, V | 1 |
| Srimuang, S | 1 |
| Tanphaichitra, D | 1 |
| Fukuyama, M | 1 |
| Furuhata, K | 1 |
| Oonaka, K | 1 |
| Hara, T | 1 |
| Sunakawa, K | 1 |
| Ortega, M | 1 |
| Alvárez, JL | 1 |
| Tomás, X | 1 |
| Soriano, E | 1 |
| Vicari, E | 1 |
| Kamei, T | 1 |
| Toriumi, Y | 1 |
| Tomioka, H | 1 |
| Scheen, AJ | 1 |
| Norrby, SR | 1 |
| Wada, K | 1 |
| Tanaka, M | 2 |
| Nickel, JC | 1 |
| Downey, J | 1 |
| Johnston, B | 1 |
| Clark, J | 1 |
| Palau, J | 1 |
| Picón, I | 1 |
| Angel Climent, M | 1 |
| Martí, R | 1 |
| Aznar, E | 1 |
| Carmen Sanjuán, M | 1 |
| Máiquez, J | 1 |
| Senneville, E | 2 |
| Yazdanpanah, Y | 1 |
| Cazaubiel, M | 1 |
| Cordonnier, M | 1 |
| Valette, M | 1 |
| Beltrand, E | 1 |
| Khazarjian, A | 1 |
| Maulin, L | 1 |
| Alfandari, S | 1 |
| Caillaux, M | 2 |
| Mouton, Y | 2 |
| Yamada, Y | 1 |
| Hu, P | 1 |
| Zou, Q | 1 |
| Jiang, Y | 1 |
| Wang, Q | 1 |
| Jiang, S | 1 |
| Hu, D | 1 |
| Zhu, L | 1 |
| Li, S | 1 |
| Zhang, Z | 1 |
| Zhen, J | 1 |
| Zhan, S | 1 |
| Stahlmann, R | 1 |
| Trinchieri, A | 1 |
| Mangiarotti, B | 1 |
| Lizzano, R | 1 |
| De Simone, C | 1 |
| Trinchieri, V | 1 |
| Tzantzoglou, S | 1 |
| Famularo, G | 1 |
| Moretti, S | 1 |
| Delia, S | 1 |
| Kosiec, T | 1 |
| Marianowski, L | 1 |
| Meisel-Mikołajczyk, F | 1 |
| Rekosz, A | 1 |
| Hosaka, M | 2 |
| Yasue, T | 1 |
| Fukuda, H | 1 |
| Tomizawa, H | 1 |
| Aoyama, H | 3 |
| Hirai, K | 2 |
| Poole, MD | 1 |
| Fu, KP | 1 |
| Lafredo, SC | 1 |
| Foleno, B | 1 |
| Isaacson, DM | 1 |
| Barrett, JF | 1 |
| Tobia, AJ | 1 |
| Rosenthale, ME | 1 |
| Morimoto, K | 1 |
| Kinoshita, H | 1 |
| Nakatani, S | 1 |
| Sakai, K | 1 |
| Fujimoto, M | 1 |
| Ohno, K | 1 |
| Ueda, T | 2 |
| Ohmori, K | 1 |
| Yamazaki, O | 1 |
| Doi, S | 1 |
| Cho, N | 1 |
| Kimura, T | 1 |
| Shimizu, A | 1 |
| Ichikawa, K | 1 |
| Fukunaga, K | 1 |
| Kunii, K | 1 |
| Matsuda, S | 1 |
| Oh, K | 1 |
| Hirayama, H | 1 |
| Sander, J | 1 |
| Sanders, CC | 1 |
| Sanders, WE | 2 |
| Lamp, KC | 1 |
| Bailey, EM | 1 |
| Rybak, MJ | 1 |
| Bravo, JL | 1 |
| Mociková, K | 1 |
| Svác, J | 1 |
| Faber, E | 1 |
| Wildová, B | 1 |
| Baníková, I | 1 |
| Tsutani, H | 1 |
| Imamura, S | 1 |
| Yoshida, H | 2 |
| Iwasaki, H | 1 |
| Fukushima, T | 1 |
| Yoshimura, T | 1 |
| Toyooka, S | 1 |
| Nakamura, T | 1 |
| Nicolau, D | 1 |
| Quintiliani, R | 1 |
| Nightingale, CH | 1 |
| Schregel, W | 1 |
| Hartmann, K | 1 |
| Schmitz, C | 1 |
| Baumgärtner, D | 1 |
| Cunitz, G | 1 |
| Eron, LJ | 1 |
| Gentry, LO | 2 |
| Todd, PA | 1 |
| Faulds, D | 1 |
| Rodriguez-Gomez, G | 1 |
| Kohler, RB | 1 |
| Khan, FA | 1 |
| Rytel, MW | 1 |
| Petermann, W | 1 |
| Feist, H | 1 |
| Watanabe, A | 1 |
| Beaucaire, G | 2 |
| Leroy, O | 2 |
| Beuscart, C | 2 |
| Karp, P | 1 |
| Chidiac, C | 2 |
| Morris, JF | 1 |
| Alessi, P | 1 |
| Makris, AT | 1 |
| McCloskey, RV | 1 |
| Trenholme, GM | 1 |
| Iannini, P | 1 |
| Bittner, MJ | 1 |
| Kleckow, M | 1 |
| Powers, RD | 1 |
| Deguchi, K | 1 |
| Yokota, N | 1 |
| Koguchi, M | 1 |
| Nakane, Y | 1 |
| Suzuki, Y | 1 |
| Fukayama, S | 1 |
| Ishihara, R | 1 |
| Oda, S | 1 |
| Mueller-Buehl, U | 1 |
| Diehm, C | 2 |
| Gutzler, F | 2 |
| Adam, D | 1 |
| Swanson, RN | 1 |
| Hardy, DJ | 1 |
| Chu, DT | 1 |
| Shipkowitz, NL | 1 |
| Clement, JJ | 1 |
| Gargallo-Viola, D | 1 |
| Esteve, M | 1 |
| Llovera, S | 1 |
| Roca, X | 1 |
| Guinea, J | 1 |
| Cheng, IK | 1 |
| Chan, CY | 1 |
| Wong, WT | 1 |
| Yamaoka, M | 1 |
| Fukuchi, Y | 1 |
| Yokouchi, M | 1 |
| Teramoto, N | 1 |
| Nagase, T | 1 |
| Ishida, K | 1 |
| Ohtomo, E | 1 |
| Orimo, H | 1 |
| Gluckman, E | 1 |
| Roudet, C | 1 |
| Hirsch, I | 1 |
| Devergie, A | 1 |
| Bourdeau, H | 1 |
| Arlet, C | 1 |
| Perol, Y | 1 |
| Youngchaiyud, P | 1 |
| Permpikul, C | 1 |
| Thamlikitkul, V | 1 |
| Charoenratanakul, S | 1 |
| Nana, A | 1 |
| Otsuki, M | 1 |
| Nishino, T | 1 |
| Garbe, C | 1 |
| Weissbach, L | 1 |
| Harbrecht, J | 1 |
| Kleinschmidt, K | 1 |
| Schiefer, HG | 1 |
| Friedrich, HJ | 1 |
| Winston, DJ | 1 |
| Ho, WG | 1 |
| Bruckner, DA | 1 |
| Gale, RP | 1 |
| Champlin, RE | 1 |
| Sivery, B | 1 |
| Vincent du Laurier, M | 1 |
| Graninger, W | 1 |
| Presterl, E | 1 |
| Walzl, B | 1 |
| Lackner, R | 1 |
| Haslinger, B | 1 |
| Hackl, W | 1 |
| Arning, M | 1 |
| Wolf, HH | 1 |
| Aul, C | 1 |
| Heyll, A | 1 |
| Scharf, RE | 1 |
| Scheider, W | 1 |
| Liang, RH | 1 |
| Yung, RW | 1 |
| Chan, TK | 1 |
| Lam, WK | 2 |
| So, SY | 2 |
| Todd, D | 1 |
| Raffi, F | 1 |
| Feve, B | 1 |
| Tiab, M | 1 |
| Brisseau, JM | 1 |
| Reynaud, AE | 1 |
| Grolleau, JY | 1 |
| Staffensky, RH | 1 |
| Stolke, D | 1 |
| Malottke, R | 1 |
| Dellamonica, P | 2 |
| Bernard, E | 2 |
| Etesse, H | 2 |
| Garraffo, R | 2 |
| Drugeon, HB | 1 |
| Waldvogel, FA | 1 |
| Fong, IW | 1 |
| Naumann, P | 1 |
| Dopp, C | 1 |
| Kosakai, N | 2 |
| Wolfson, JS | 1 |
| Cox, CE | 1 |
| Leung, YK | 1 |
| Chan, JC | 1 |
| Ip, M | 1 |
| Sham, MK | 1 |
| Cristiano, P | 2 |
| Iovene, MR | 1 |
| Morelli, G | 2 |
| Mandia, L | 1 |
| Paradisi, F | 2 |
| Altucci, P | 2 |
| Fung-Tomc, J | 1 |
| Desiderio, JV | 1 |
| Tsai, YH | 1 |
| Warr, G | 1 |
| Kessler, RE | 1 |
| Brouqui, P | 1 |
| Aubaniac, JM | 1 |
| Curvale, G | 1 |
| Groulier, P | 1 |
| Raoult, D | 1 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Davies, BI | 3 |
| Maesen, FP | 3 |
| Teengs, JP | 2 |
| Baur, C | 3 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Høiby, N | 1 |
| Fujii, T | 1 |
| Lopitaux, R | 1 |
| Hermet, R | 1 |
| Sirot, J | 1 |
| Terver, S | 1 |
| Levai, JP | 1 |
| Belovezhdov, N | 1 |
| Angelova, I | 1 |
| Talakova, Ch | 1 |
| Demoleas, SE | 1 |
| Davies, GF | 1 |
| Musiał, J | 1 |
| Sładek, K | 1 |
| Kotlinowska, T | 1 |
| Szczeklik, A | 1 |
| Umeki, S | 1 |
| Okamoto, Y | 1 |
| Hisamoto, N | 1 |
| Hara, Y | 1 |
| Anders, CU | 1 |
| Höfeler, H | 1 |
| Schmidt, CG | 1 |
| Suermondt, G | 1 |
| Denamur, E | 1 |
| Laurans, G | 1 |
| Grossi, P | 1 |
| Malfitano, A | 1 |
| Perversi, L | 1 |
| Kapidzić, A | 1 |
| Zulić, I | 1 |
| Braunstajn, Z | 1 |
| Mahmutović, E | 1 |
| Drew, RH | 1 |
| Gallis, HA | 1 |
| Monk, JP | 1 |
| Campoli-Richards, DM | 1 |
| Bruch, K | 2 |
| Blomer, R | 2 |
| Chavanet, P | 1 |
| Arnould, S | 1 |
| Sarret, Y | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Portier, H | 1 |
| Giaume, F | 1 |
| Walker, RC | 1 |
| Wright, AJ | 1 |
| Hartlapp, JH | 1 |
| Shah, PM | 2 |
| Lenarz, T | 1 |
| Schulz, W | 1 |
| Dörfler, A | 1 |
| Sumajow, CA | 1 |
| Stahl, JP | 1 |
| Croize, J | 1 |
| Lefèbvre, MA | 1 |
| Bru, JP | 1 |
| Guyot, A | 1 |
| Leduc, D | 1 |
| Fourtillan, JB | 1 |
| Micoud, M | 1 |
| Müller-Bühl, U | 1 |
| el-Baz, W | 1 |
| Osman, L | 1 |
| Abd-el-Hamid, T | 1 |
| el-Bokl, M | 1 |
| Sabbour, MS | 1 |
| Periti, P | 1 |
| Mazzei, T | 1 |
| Nicoletti, P | 1 |
| Gubina, M | 1 |
| Wolff, M | 1 |
| Hirose, T | 1 |
| Okezaki, E | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Thorn, V | 1 |
| Grcić, R | 1 |
| Ivanović, L | 1 |
| Stavrić, V | 1 |
| Kadija, D | 1 |
| Miković, Z | 1 |
| Tsagarakis, J | 1 |
| Zahlten, RN | 1 |
| Rubinstein, E | 1 |
| Mark, Z | 1 |
| Keren, G | 1 |
| Alkan, M | 1 |
| Berger, S | 1 |
| Bogokowski, B | 1 |
| Knothe, H | 1 |
| Roekaerts, F | 1 |
| Deleers, L | 1 |
| Wittenberger, R | 1 |
| Katsu, M | 1 |
| Peyramond, D | 1 |
| Tigaud, S | 1 |
| Lucht, F | 1 |
| Vedrinne, JM | 1 |
| Salord, F | 1 |
| Bertrand, JL | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Neu, HC | 2 |
| Cynamon, MH | 1 |
| Wilcox, GH | 1 |
| Fritzen, T | 1 |
| Marx, E | 1 |
| Uy, J | 1 |
| Leonessa, V | 1 |
| Briante, V | 1 |
| Baba, S | 1 |
| Eggleston, M | 1 |
| Park, SY | 1 |
| Fuchs, PC | 1 |
| Barry, AL | 1 |
| Thornsberry, C | 1 |
| Sawatari, K | 1 |
| Fukuda, Y | 1 |
| Nagasawa, M | 1 |
| Tomonaga, A | 1 |
| Nakazato, H | 1 |
| Shigeno, Y | 1 |
| Suzuyama, Y | 1 |
| Kumada, T | 1 |
| Altay, G | 1 |
| Tulunay, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics[NCT01539811] | 2 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Principal investigator decided to terminate the study.) | |||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563394] | Phase 3 | 584 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563433] | Phase 3 | 342 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486] | 1,257 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808] | Phase 3 | 383 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)[NCT00434291] | Phase 2 | 264 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384] | 547 participants (Anticipated) | Observational [Patient Registry] | 2016-12-31 | Recruiting | |||
| A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors[NCT00005590] | Phase 3 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat[NCT00044473] | Phase 3 | 206 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| [NCT00042718] | Phase 3 | 659 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders That Occur After Initiating a Course of Levofloxacin (RWJ-25213-097) or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Cli[NCT00210639] | 2,233 participants (Actual) | Observational | 2002-08-31 | Completed | |||
| Concentration of Ofloxacin Into the Aqueous Humour of Patients After Topical Instillation According to the Severity of Dry Eye Disease[NCT05213156] | Phase 4 | 91 participants (Actual) | Interventional | 2019-09-24 | Completed | ||
| Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study[NCT05302531] | Phase 1 | 10 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The criteria used to assess Musculoskeletal Adverse Event is based on system organ class Musculoskeletal and connective tissue disorders of MedDRA 13.0." (NCT00210639)
Timeframe: Musculoskeletal Disorder (MSD) Follow-Up phase (ie, up to 5 years after their first dose of antimicrobial therapy, yearly visits for 4 additional years)
| Intervention | Participants (Number) |
|---|---|
| Levofloxacin | 3 |
| Comparator | 3 |
43 reviews available for ofloxacin and Bacterial Infections
| Article | Year |
|---|---|
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Mic | 2019 |
[Present positioning of levofloxacin in chemotherapy of bacterial infections].
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Levofloxacin; Ofloxacin | 2008 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin | 2009 |
[From cystitis to bacterial prostatitis: experience with levofloxacin].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cystitis; Double-Blind Method; Drug Therapy, Combinatio | 2009 |
Levofloxacin revisited.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Gastrointestinal Diseases; Humans; Levofloxaci | 2011 |
[Treatment and prevention of infections in cancer patients with neutropenia].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacterial In | 2011 |
Levofloxacin: an updated review of its use in the treatment of bacterial infections.
Topics: Bacterial Infections; Clinical Trials as Topic; Gram-Negative Bacteria; Humans; Levofloxacin; Ofloxa | 2002 |
Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Topics: Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availability; Gram-Negativ | 2003 |
Comparative antimicrobial susceptibility of respiratory tract pathogens.
Topics: Asia, Eastern; Bacterial Infections; Drug Resistance, Microbial; Humans; Levofloxacin; Macrolides; M | 2004 |
[Levofloxacin: role and place in the treatment of infections of the lower respiratory tracts].
Topics: Anti-Bacterial Agents; Bacterial Infections; Central Nervous System; Drug Resistance, Bacterial; Hum | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistanc | 2005 |
[Levofloxacin nowadays].
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Bacterial; Humans; Levofloxacin; Oflox | 2006 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response | 2007 |
[Levofloxacin and other antibacterial drugs].
Topics: Anti-Bacterial Agents; Bacterial Infections; Dermatitis; Dosage Forms; Humans; Levofloxacin; Ofloxac | 2006 |
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Community-Acquired Infections; Drug Resistance | 2008 |
Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
Topics: Administration, Oral; Aging; Bacteria; Bacterial Infections; Biological Availability; Drug Interacti | 1994 |
[[New antimicrobial agent series XLVII]: levofloxacin].
Topics: Absorption; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Bacterial Infections; | 1994 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levoflox | 1996 |
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Levofloxac | 1997 |
Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Drug Resistance; Female | 1998 |
New fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pipe | 1999 |
[Levofloxacin for prevalent infections in primary care medicine].
Topics: Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Humans; Levofloxacin; Of | 1999 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; M | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Pi | 2000 |
Levofloxacin.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Clinical Trials as Topic; Humans; Le | 1999 |
[Injectable quinolones].
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Injections, Intravenous | 2001 |
[Use of levofloxacin in the antibiotic prophylaxis for diagnostic procedures in urology].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinar | 2002 |
[Fluoroquinolones--a new and important group of antimicrobial agents].
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Oflo | 1992 |
Review of preclinical studies with ofloxacin.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Mic | 1992 |
Oral ofloxacin: a critical review of the new drug application.
Topics: Administration, Oral; Bacterial Infections; Humans; Ofloxacin | 1992 |
Ofloxacin clinical pharmacokinetics.
Topics: Absorption; Aged; Aged, 80 and over; Bacterial Infections; Drug Interactions; Humans; Kidney; Kidney | 1992 |
Ofloxacin vs ciprofloxacin: a comparison.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Metabolic Clearance Rate; Microbial Sensitivity Tests; | 1992 |
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
Topics: Bacterial Infections; Drug Interactions; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; | 1991 |
Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Humans; Norfloxacin; Ofloxacin | 1989 |
Quinolones. Oral antibiotics of the future.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Foot Diseases; Humans; Microbial Sensitiv | 1988 |
Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Int | 1988 |
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Kinetics; Ofloxacin; Oxazines | 1987 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1987 |
Quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Enoxacin | 1987 |
[Ofloxacin].
Topics: Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biotran | 1986 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; C | 1987 |
The role of 4-quinolones in the treatment of infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra | 1987 |
Review of the 4-quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Drug Resist | 1987 |
93 trials available for ofloxacin and Bacterial Infections
| Article | Year |
|---|---|
Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Chronic Disease; Gram-Negative Bacteria; Gram-Po | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
[The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Female; Hum | 2009 |
Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacteria | 2009 |
[A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Double-Blind Method; Female; H | 2011 |
Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chem | 2011 |
Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Body Weight; Chromat | 2012 |
Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchit | 2002 |
[Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Drug Administra | 2002 |
Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial In | 2003 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met | 2003 |
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibili | 2004 |
Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxa | 2004 |
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Disease Pr | 2004 |
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Topics: Amyloidosis; Anemia, Aplastic; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; | 2005 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; | 2005 |
[Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications].
Topics: Acute Disease; Adolescent; Adult; Africa, Southern; Aged; Bacterial Infections; Female; France; Haem | 2005 |
Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacte | 2005 |
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacte | 2005 |
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineopl | 2005 |
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Br | 2006 |
An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child, Preschool; Exudates and | 2006 |
Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity.
Topics: Acute Disease; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromy | 2007 |
Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Female; Humans; In | 2007 |
Rational selection of patients for antibacterial prophylaxis after chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; D | 2007 |
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Female; Humans; Levofloxacin; Male; Ma | 2008 |
Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy; Cystitis; Fluoroq | 2008 |
[Comparative clinical study of DL-8280 and cefaclor for suppurative skin and soft tissue infections by a double-blind method].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cefaclor; Cephalexin; Clinical Trials as T | 1984 |
[Comparative clinical study of ofloxacin and cefaclor in bacterial bronchitis].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; Cefaclor; Cephalexin; Clinical | 1984 |
[Comparison of clinical efficacy of ofloxacin COFLX: DL-8280) and pipemidic acid (PPA) in acute infectious diarrhea by a double-blind method. The Japan Research Committee of Ofloxacin, Research Group for Acute Infectious Diarrhea].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Campylobacter I | 1984 |
Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Granulocyte | 1993 |
[Clinical efficacy of ciprofloxacin and ofloxacin].
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Dysentery, Bacillary; Female; Gonorrhe | 1994 |
Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage.
Topics: Adult; Amoxicillin; Bacterial Infections; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combinati | 1994 |
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
Topics: Adult; Aged; Agranulocytosis; Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin | 1994 |
[A new therapeutic strategy using a ofloxacin-amoxicillin-clavulanic acid combination in the treatment of upper gynecologic infections. Apropos of 123 cases].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibito | 1994 |
Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study.
Topics: Adult; Bacterial Infections; Drug Costs; Drug Therapy, Combination; Female; Fluconazole; Humans; Inc | 1993 |
Single-drug oral antibacterial prophylaxis with ofloxacin in BMT recipients.
Topics: Administration, Oral; Adolescent; Adult; Bacterial Infections; Bone Marrow Transplantation; Drug Tol | 1993 |
Effectiveness and safety of ofloxacin in chronic otitis media and chronic sinusitis in adult outpatients.
Topics: Administration, Oral; Adult; Ambulatory Care; Bacterial Infections; Chronic Disease; Humans; Ofloxac | 1993 |
Clinical experiences with ofloxacin sequential therapy in chronic ear infections.
Topics: Administration, Oral; Adult; Bacterial Infections; Chronic Disease; Drug Administration Schedule; Fe | 1993 |
Once-daily ofloxacin for hospitalised patients with severe bacterial infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Hospitalization | 1995 |
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; C | 1996 |
The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chem | 1996 |
Oral antimicrobials in compound fracture of the hand: comparison of dicloxacillin and ofloxacin.
Topics: Accidents, Occupational; Adolescent; Adult; Anti-Infective Agents; Bacterial Infections; Dicloxacill | 1996 |
[Clinico-pharmacologic aspects of the use of ofloxacin].
Topics: Anti-Infective Agents; Antibody Formation; Bacterial Infections; Biliary Tract Diseases; Bronchial D | 1996 |
[Antibiotic use in necrotizing pancreatitis. Results of a controlled study].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Biopsy, Needle; Drug Th | 1997 |
Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Cost-Benefit Analysis; Delivery of Health C | 1997 |
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Bayes Theorem; Dose-Response R | 1998 |
New criteria for management of catheter infections in peritoneal dialysis patients using ultrasonography.
Topics: Abdominal Abscess; Adult; Aged; Bacterial Infections; Catheters, Indwelling; Female; Follow-Up Studi | 1998 |
Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Topics: Acute Disease; Adult; Anti-Infective Agents; Bacterial Infections; Exudates and Transudates; Female; | 1998 |
Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Amoxicillin-Potassium Clavulanate Comb | 1998 |
Quinolones for short-term treatment of uncomplicated urinary tract infection.
Topics: 4-Quinolones; Administration, Oral; Adult; Anti-Infective Agents; Bacterial Infections; Female; Fluo | 1999 |
Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administ | 2000 |
An open, non comparative study of ofloxacin i.v. on the treatment of acute symptomatic urinary tract infection.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Dose-Response Relationship, Drug; Drug | 2000 |
[Tolerability and safety of levofloxacinin long-term treatment].
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Humans; Levofloxacin; | 2000 |
Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Doxycycline; Epididymitis; Femal | 2000 |
Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibodies, Bacterial; Bacteria; Bacterial In | 2001 |
[A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Female; Fluoroquinolones; Huma | 1999 |
AIDS patients with bacterial lower respiratory tract infections: treatment with ofloxacin versus sulbactam-ampicillin.
Topics: Adult; AIDS-Related Opportunistic Infections; Ampicillin; Bacterial Infections; Drug Therapy, Combin | 1992 |
Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Female; Human | 1992 |
Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Diabetes Complications; Drug Resistance, Mi | 1992 |
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
Topics: Bacterial Infections; Drug Interactions; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; | 1991 |
Sequential therapy with i.v. and oral ofloxacin in lower respiratory tract infections: a comparative study.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacte | 1991 |
Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchiectasis; Bronchitis; Chr | 1991 |
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Cefotaxime; Ceftazidime; Cross Infection; Drug Administ | 1991 |
Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Humans; Male; Mi | 1991 |
[Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Cefuroxime; Chronic Di | 1991 |
Soft tissue infections in the emergency department: the case for the use of 'simple' antibiotics.
Topics: Adult; Ambulatory Care; Bacterial Infections; Cephalexin; Connective Tissue Diseases; Drug Administr | 1991 |
Tissue concentrations of ofloxacin in necrotic foot lesions of diabetic and non-diabetic patients with peripheral arterial occlusive disease.
Topics: Aged; Bacterial Infections; Diabetic Angiopathies; Diabetic Neuropathies; Female; Foot; Humans; Isch | 1991 |
A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).
Topics: Administration, Oral; Aztreonam; Bacterial Infections; Drug Therapy, Combination; Humans; Ofloxacin; | 1991 |
Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin).
Topics: Adolescent; Adult; Amoxicillin; Bacterial Infections; Bone Marrow Transplantation; Drug Therapy, Com | 1991 |
Treatment of community-acquired pneumonia with ofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bacterial Infections; Female; Humans; Male; Microbial | 1991 |
Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacteria; Bacterial Infections; Digestive System; Drug The | 1990 |
Clinical experience with parenteral and oral ofloxacin in severe infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria, Aerobic; Bacterial Infec | 1990 |
Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Fran | 1990 |
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.
Topics: Bacterial Infections; Ciprofloxacin; Colistin; Humans; Neutropenia; Ofloxacin; Precursor Cell Lympho | 1990 |
Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Child; Female | 1990 |
The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Dermatitis; En | 1989 |
[Susceptibilities of clinical isolates to antibacterial agents. A study mainly focused on ofloxacin (the second report). Reported by the Research Group for Testing ofloxacin Susceptibility on Clinical Isolates].
Topics: Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Multicenter Studies as Topic; Of | 1989 |
Ofloxacin in the management of complicated urinary tract infections, including prostatitis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Carbenicillin; Drug Resistance, Microbial; | 1989 |
Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis.
Topics: Adult; Amoxicillin; Bacteria; Bacterial Infections; Bronchiectasis; Double-Blind Method; Female; Hum | 1989 |
[Clinical trial of ofloxacin (Tarivid R)].
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Hum | 1988 |
[Effectiveness of ofloxacin in the treatment of bacterial infections of the respiratory tract].
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Oflo | 1988 |
Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Int | 1988 |
Efficacy and safety of ofloxacin in elderly patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Fema | 1987 |
Antimicrobial prophylaxis in immunocompromised patients.
Topics: Adult; Agranulocytosis; Anti-Infective Agents; Antineoplastic Agents; Bacterial Infections; Clinical | 1987 |
Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Drug Therapy, Combination; Fe | 1986 |
[Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe].
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Drug Resista | 1986 |
[Respiratory tract infections--clinical results with ofloxacin].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Clinical Trials as | 1986 |
[Effectiveness of ofloxacin in the treatment of wound infections].
Topics: Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Clinical Trials as Topic; Dose-Respons | 1986 |
[Ofloxacin versus pipemidic acid and co-trimoxazole].
Topics: Adult; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Clinical Trials as Topic; Dos | 1986 |
Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topi | 1986 |
Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cholangitis; Clinical Trials a | 1986 |
Clinical efficacy of ofloxacin in the treatment of otorhinolaryngological infections.
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Humans; Laryngitis; Ofloxacin | 1986 |
160 other studies available for ofloxacin and Bacterial Infections
| Article | Year |
|---|---|
Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Carboxylic Acids; Escherichia coli; Fluoroquin | 1993 |
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Topics: Acylation; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bartonella; Bartonella Infections; | 2012 |
The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Design; Enzyme Inhibitors; Histidine Kin | 2016 |
Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Candida albicans; Candidia | 2017 |
Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Bacterial Infections; Dose-Response Relationship | 2022 |
[Corneal cross-linking in microbial keratitis to prevent à chaud keratoplasty: a retrospective case series].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Biological Dressings; C | 2014 |
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime | 2010 |
Prophylactic use of isepamicin and levofloxacin for transrectal prostate biopsy: a retrospective single center study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy | 2009 |
Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Computer Simulation; Female; H | 2010 |
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infect | 2009 |
Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Cohort Studies; Doxycycline; Drug Resistance, Bacteria | 2010 |
Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug | 2010 |
[Levofloxacin in children].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Community-Acquired Infections; Humans; Le | 2010 |
First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Circular Dichroism; Crystallography, X-Ray; D | 2010 |
[Practice management of chronic bacterial prostatitis with levofloxacin].
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Chronic Disease; Escherichia coli | 2011 |
Prevalence and risk factors for unsuspected spontaneous ascitic fluid infection in cirrhotics undergoing therapeutic paracentesis in an outpatient clinic.
Topics: Adult; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefotaxime; Drug Therapy, Combina | 2011 |
Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacte
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Cipr | 2011 |
Critical appraisal of air pouch infection model in rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re | 2012 |
Levofloxacin-associated panuveitis with chorioretinal lesions.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Bites and Stings; Female; | 2012 |
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxaci | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
[Fluoroquinolone superior to macrolide. Longer infection free period after acute bronchitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bronchitis; Clarithromycin; Doub | 2003 |
Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy.
Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Aged, 80 and over; Antibi | 2003 |
[Use of levofloxacin in the hospital].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cross Infec | 2003 |
[Observational study investigating the use of levofloxacin in ICU patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Arrhythmias, Cardiac; B | 2004 |
[A prospective study on short period antibiotic treatment of hepatic failure complicated with spontaneous bacterial peritonitis].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Drug Therapy, Combination; Female; | 2004 |
Tissue and serum levofloxacin concentrations in diabetic foot infection patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Chromatography, High Pressure Liq | 2004 |
Antibiotics in exacerbations of COPD: lessons from the past.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Disease Progression; Humans; Ofloxacin; | 2004 |
[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Community-Acquired Infections; Escherichia col | 2005 |
Editorial commentary: dilemma in trial design: do current study designs adequately evaluate effectiveness antibiotic in ABRS?
Topics: Acute Disease; Azithromycin; Bacterial Infections; Chemistry, Pharmaceutical; Dose-Response Relation | 2005 |
Prophylactic antimicrobial agents and the importance of fitness.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Drug Res | 2005 |
[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Ce | 2005 |
Evaluation of ofloxacin activity against recent clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Microbial Sensitivity Tests; Ofloxaci | 1989 |
A review of the therapeutic uses of ofloxacin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic | 1989 |
Efficacy of ofloxacin taken orally in 19 severe infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Clinical | 1989 |
The activity of ofloxacin compared to spiramycin in oral surgery.
Topics: Bacterial Infections; Clinical Trials as Topic; Humans; Ofloxacin; Oral Surgical Procedures; Postope | 1989 |
Ofloxacin in the treatment of genito-urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Female Urogenital Disea | 1989 |
Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Escherichia coli Infec | 1989 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia; | 2006 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia; | 2006 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Hum | 2006 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Drug Resistance, Mult | 2006 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacteri | 2006 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Fever; Hospitalization; Humans; | 2006 |
Value of short-course antimicrobial therapy in acute bacterial rhinosinusitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Dose-Response Relat | 2005 |
Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Corne | 2007 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; | 2006 |
Treatment of acute post-surgical infection of joint arthroplasty.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2006 |
Post-marketing surveillance of the safety of levofloxacin in Japan.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Chemical and | 2007 |
Time to abandon Ofloxacin?
Topics: Anti-Bacterial Agents; Bacterial Infections; Fluoroquinolones; Humans; Ofloxacin; Pakistan; Topoisom | 2007 |
Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Female; Humans; Levofloxacin; | 2007 |
Acute bacterial sacroiliitis in an adult: a case report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Clindamycin; Female; Humans; Joint Diseases; Low | 2007 |
Commentary on "Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis" by Ambrose et al.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Levofloxacin; Maxillary Sinusitis; Ofloxacin | 2008 |
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Topics: Bacteria; Bacterial Infections; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Napht | 1984 |
[Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Evalu | 1984 |
In vitro and in vivo activity of DL-8280, a new oxazine derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Male; Mice; Microbial Sensitivity Te | 1982 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
Bacteriology of chronic suppurative otitis media: ofloxacin susceptibility.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Female; Human | 1995 |
Effect of inflammation on intraocular penetration of intravenous ofloxacin in albino rabbits.
Topics: Animals; Bacterial Infections; Endophthalmitis; Eye; Ofloxacin; Rabbits | 1995 |
Stability of ofloxacin in peritoneal dialysis solutions.
Topics: Bacterial Infections; Chromatography, High Pressure Liquid; Dialysis Solutions; Drug Stability; Huma | 1995 |
The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Ofloxacin | 1994 |
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Topics: Bacteria; Bacterial Infections; Canada; Ciprofloxacin; Enterobacteriaceae; Female; Genitalia; Humans | 1994 |
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; Gram-P | 1994 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria | 1993 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
An audit of ciprofloxacin use in a district general hospital.
Topics: Anti-Infective Agents; Bacterial Infections; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Ut | 1995 |
In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Micr | 1995 |
Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; China; Clin | 1995 |
Effect of levofloxacin-albumin Dacron graft on graft infection.
Topics: Animals; Bacterial Infections; Levofloxacin; Male; Ofloxacin; Polyethylene Terephthalates; Rats; Rat | 1995 |
Treatment of spontaneous bacterial peritonitis with oral ofloxacin: inpatient or outpatient therapy?
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Humans; Ofloxacin; Peritonitis | 1996 |
[Use of ofloxacin in infections which do not readily respond to treatment].
Topics: Anti-Infective Agents; Bacterial Infections; Biological Availability; Drug Resistance, Microbial; Gr | 1996 |
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Dru | 1997 |
In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Fluoro | 1997 |
[Stage-oriented antibiotic therapy of peritonitis. Prospective study].
Topics: Anti-Infective Agents; Bacterial Infections; Cefotaxime; Cephalosporins; Combined Modality Therapy; | 1997 |
Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Diabetic | 1998 |
Changes in white blood cell counts in men undergoing thrice-weekly prostatic massage, microbial diagnosis and antimicrobial therapy for genitourinary complaints.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antibiotics, Antineoplastic; Bacterial Infections; Drug | 1998 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1998 |
IL-1ra versus IL-1 levels in prostatic fluid from prostatitis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Body Fluids; C | 1998 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infe | 1998 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; | 1999 |
Can quinolones cause hemorrhagic colitis of late onset? Report of three cases.
Topics: Acute Disease; Adult; Anti-Infective Agents; Bacterial Infections; Colitis; Colonoscopy; Enoxacin; F | 1999 |
[In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Topics: Ampicillin; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefaclor; Cefpodoxime; Ceftizoxim | 1999 |
[Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Blood; Campylobacter; Electrolyt | 2000 |
[Treatment in general practice. Effective, well tolerated therapy].
Topics: Anti-Infective Agents; Bacterial Infections; Humans; Ofloxacin; Respiratory Tract Infections; Treatm | 2000 |
Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Body | 2000 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchit | 2000 |
[Infection in patients with neutropenia that undergo an autologous peripheral blood stem cell transplant due to breast cancer].
Topics: Acyclovir; Adult; Anti-Infective Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Pro | 2001 |
Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Antibiotics, Antitubercular; Bacterial Infections | 2001 |
[A case of acute focal bacterial nephritis].
Topics: Acute Disease; Adult; Bacterial Infections; Ceftazidime; Drug Therapy, Combination; Female; Focal In | 2001 |
[Adverse drug reaction and rational use of levofloxacin: a prospective study].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anti-Infective Agents; Bacterial | 2001 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
[Results of treatment with ofloxacin for inflammatory conditions in male reproductive organs].
Topics: Adult; Bacterial Infections; Genital Diseases, Male; Humans; Infertility, Male; Male; Ofloxacin | 1992 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Dr | 1992 |
Limiting the use of the quinolones--ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Oflo | 1992 |
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Levofloxacin; Mice; Microbial Sensit | 1992 |
Efficacy of a new quinolone, levofloxacin in patients with surgical infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Humans; Levofloxacin; Male; Middle Age | 1992 |
[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology].
Topics: Administration, Oral; Adult; Bacterial Infections; Female; Genital Diseases, Female; Humans; Levoflo | 1992 |
[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrical and gynecological field].
Topics: Administration, Oral; Adult; Bacterial Infections; Female; Genital Diseases, Female; Humans; Levoflo | 1992 |
[Ofloxacin: a new ally in the treatment of urinary infections and bacterial prostatitis].
Topics: Bacterial Infections; Humans; Male; Ofloxacin; Prostatitis; Urinary Tract Infections | 1992 |
[Comparison of Tarivid and Biseptol in the prevention of bacterial infections in patients with acute leukemia].
Topics: Bacterial Infections; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Ofloxacin; Precur | 1992 |
[An infected fistula following a peridural catheter].
Topics: Aged; Bacterial Infections; Catheters, Indwelling; Epidural Space; Female; Fistula; Humans; Ofloxaci | 1992 |
Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cross Infection; Female; | 1992 |
Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.
Topics: Abdomen; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Drug Synergism; Female; Hu | 1991 |
Ofloxacin in lower respiratory tract infections.
Topics: Bacterial Infections; Bronchitis; Chronic Disease; Cross Infection; Drug Administration Schedule; Dr | 1991 |
[Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
Topics: Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Ofl | 1991 |
New perspectives on ofloxacin. Proceedings of a symposium. West Berlin, 16 October 1989.
Topics: Bacterial Infections; Humans; Ofloxacin | 1990 |
Antimicrobials in the '90s: expanded options for effective patient care. Proceedings of a symposium on ofloxacin. May 4-5, 1990.
Topics: Animals; Bacterial Infections; Humans; Ofloxacin | 1991 |
Activity of temafloxacin against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Dose-Response | 1991 |
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Prec | 1991 |
Efficacy of oral administration of ofloxacin in lower respiratory tract infections in aged patients with chronic lung disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Chronic Disease; Fe | 1991 |
Ofloxacin.
Topics: Bacteria; Bacterial Infections; Humans; Microbial Sensitivity Tests; Ofloxacin | 1991 |
In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Hydrogen-Ion Concentration; I | 1990 |
[Initial therapy of acute unilateral epididymitis using ofloxacin. I. Clinical and microbiological findings].
Topics: Acute Disease; Adult; Bacterial Infections; Bacteriuria; Chlamydia trachomatis; Epididymitis; Follow | 1990 |
Intravenous ofloxacin in severe infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Humans; Injections, Intrav | 1990 |
[Empirical treatment of febrile episodes in granulocytopenic patients with a combination of piperacillin and ofloxacin. Preliminary study].
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Bacterial Infections; Drug Therapy, Combination; Fe | 1990 |
[Cerebrospinal fluid penetration of ofloxacin (Tarivid) in non-inflamed meninges].
Topics: Adenoma; Administration, Oral; Adult; Bacterial Infections; Blood-Brain Barrier; Female; Humans; Mal | 1990 |
Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.
Topics: Administration, Oral; Adult; Bacterial Infections; Ciprofloxacin; Drug Evaluation; Escherichia coli; | 1989 |
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1989 |
Clinical role of the quinolones today and in the future.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Protocols; Forecasting; Humans; | 1989 |
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relations | 1989 |
Clinical experience with ofloxacin (DL-8280) in the therapy of various infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Child; Female; Gastroenteritis; Humans; Male; Middle | 1989 |
In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Mac | 1989 |
[Treatment of osteo-articular infections with ofloxacin. Preliminary study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone Diseases; Drug Therapy, Combi | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; D | 1986 |
Antibacterial activity of ofloxacin and its mode of action.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Escherichia coli; Mice; Ofloxacin; O | 1986 |
[Our experience with ofloxacin in the treatment of osteoarticular infections].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Hip Prosthesis; | 1988 |
[Development of Aeromonas hydrophila septicemia in a young healthy woman].
Topics: Adult; Aeromonas; Bacterial Infections; Drug Therapy, Combination; Female; Humans; Moxalactam; Oflox | 1988 |
Treatment with ofloxacin and its concentration in the cerebrospinal fluid.
Topics: Anti-Infective Agents; Bacterial Infections; Humans; Ofloxacin; Oxazines | 1988 |
[In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; In Vitro Techniques; Microbial S | 1988 |
[Susceptibilities of clinical isolates to antibacterial agents. Focusing mainly on ofloxacin (first report). Reported by the Research Group for Testing Ofloxacin Susceptibility of Clinical Isolates].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Drug Resistance, Microbial; | 1988 |
Focus on ofloxacin--a new 4-quinolone antimicrobial agent. An international workshop. London, 11-12 January 1988.
Topics: Bacterial Infections; Humans; Ofloxacin | 1988 |
Clinical safety and efficacy of ofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Drug Evaluation; Female; Humans; Male; Middle | 1988 |
[Evaluation of the effect of ofloxacin, a new chemotherapeutic agent].
Topics: Adult; Bacterial Infections; Candidiasis, Vulvovaginal; Cephalexin; Female; Genital Diseases, Female | 1988 |
[Treatment of bacterial infections by ofloxacin. 42 cases].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Drug Therapy, Combination; Drug Tolerance; | 1987 |
[Bone infections: treatment by ofloxacin. Apropos of 10 cases].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Enterobacteriaceae Infections; | 1987 |
[Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences].
Topics: Acute Disease; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Humans; Oflox | 1986 |
[Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
Topics: Adult; Aged; Aluminum Hydroxide; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Cre | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
Ofloxacin II.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Ofloxacin; Oxazines | 1986 |
Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Female; Humans; Male; Meningitis; Meningitis, Me | 1986 |
Tissue concentrations of ofloxacin in necrotic lesions in patients with peripheral vascular disease and in diabetics.
Topics: Aged; Anti-Infective Agents; Arterial Occlusive Diseases; Bacterial Infections; Diabetic Angiopathie | 1986 |
Ofloxacin therapy of difficult-to-treat infections due to multiresistant organisms.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteriuria; Drug Re | 1987 |
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1987 |
A comparative study of the sensitivity of bacteria of various origin to ofloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Microbial | 1987 |
[Therapeutic contribution of the new quinolones].
Topics: Anti-Infective Agents; Bacterial Infections; Biotransformation; Chemical Phenomena; Chemistry; Cipro | 1987 |
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Male; Mice; Microbial Sensit | 1987 |
Tissue concentrations of ofloxacin in the middle ear.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ear, Mid | 1987 |
[Ofloxacin in the treatment of gynecologic and obstetrical infections].
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Female; Genital Diseases, Female; Humans; Middle | 1987 |
Efficacy and tolerance of oral ofloxacin in treating various infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Drug Tol | 1987 |
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship, | 1986 |
[Evaluation of the use of ofloxacin in the treatment of various infections].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Blood Bactericidal Activity; D | 1986 |
[Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cystitis; Female; Humans; Male; Middle Age | 1986 |
Proposed disk diffusion susceptibility criteria for ofloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Microbial | 1985 |
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Guinea Pigs; Humans; In Vitro Techniques; Legi | 1985 |
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1985 |
[Anti-bacterial effect of ofloxacin--in vitro and in vivo results].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Enterobacteriaceae; Humans; Microbial Sensiti | 1985 |